Registration Links (4 Options)
Speakers Reg Patient Reg Reg for Clinical Trials Community Network
Logo

Gene Therapy & Genetic Medicine

Principles of cellular reprogramming, viral and non-viral vectors, CRISPR gene editing, and cellular immunotherapies in cancer care.

What is Gene Therapy?

Gene therapy is a specialized medical approach that treats or prevents human disease by modifying, replacing, or editing cellular genetic material. By correcting defective genetic sequences at their molecular origin, gene therapies deliver durable, potentially curative therapeutic outcomes for monogenic hereditary diseases, severe hematological disorders, and refractory malignancies.

Primary Gene Therapy Delivery Mechanisms

Approach Delivery Modality Clinical Description Key Applications
Ex Vivo Cellular Modification Autologous cell collection → Laboratory transduction → Reinfusion Patient cells (e.g., T-cells, CD34+ hematopoietic stem cells) are harvested, genetically engineered in a specialized facility, and returned to the patient. Chimeric Antigen Receptor (CAR) T-Cell Therapy, Sickle Cell Disease, β-Thalassemia
In Vivo Targeted Delivery Direct systemic intravenous or localized tissue injection Engineered viral vectors (Adeno-Associated Virus - AAV, Lentivirus) or lipid nanoparticles deliver transgenes directly into target tissues inside the patient. Spinal Muscular Atrophy, Inherited Retinal Dystrophies, Hemophilia A/B

Core Molecular Strategies

  • Gene Addition (Augmentation): Introducing a functional cDNA copy of a gene to compensate for a missing or non-functional mutated allele.
  • Precision Gene Editing (CRISPR-Cas9, Base Editing): Utilizing sequence-specific endonuclease ribonucleoproteins to introduce targeted double-strand breaks or direct nucleotide transitions.
  • Gene Silencing (RNA Interference & ASOs): Employing short interfering RNAs (siRNAs) or antisense oligonucleotides to degrade oncogenic mRNA transcripts and halt toxic protein synthesis.

Major Oncology Applications: CAR T-Cell Therapy

In oncology, gene therapy has achieved clinical success through Chimeric Antigen Receptor (CAR) T-cell therapy:

  • Autologous T-lymphocytes are genetically modified with a synthetic receptor combining an extracellular antigen-binding domain (e.g., anti-CD19, anti-BCMA) with intracellular CD3ζ and 4-1BB / CD28 co-stimulatory signaling domains.
  • Engineered CAR T-cells recognize and lyse target malignant cells independently of Major Histocompatibility Complex (MHC) presentation.
  • Approved for relapsed/refractory Diffuse Large B-Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, and Multiple Myeloma.

Clinical Indications & FDA-Approved Therapies

  • Hematological Oncology: Tisagenlecleucel, Axicabtagene ciloleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel, Ciltacabtagene autoleucel, Idecabtagene vicleucel.
  • Hemoglobinopathies: Exagamglogene autotemcel (CRISPR/Cas9 BCL11A enhancer editing) and Lovotibeglogene autotemcel for Sickle Cell Disease.
  • Neuromuscular & Monogenic Disorders: Onasemnogene abeparvovec (SMA), Voretigene neparvovec (RPE65 retinal dystrophy), Beremagene geperpavec (Dystrophic Epidermolysis Bullosa).
Gene therapy requires comprehensive multidisciplinary evaluation, specialized cellular processing facilities, and dedicated monitoring for immune-effector toxicities (such as Cytokine Release Syndrome and ICANS).